715 related articles for article (PubMed ID: 19545680)
1. Clinical application of Cordyceps sinensis on immunosuppressive therapy in renal transplantation.
Li Y; Xue WJ; Tian PX; Ding XM; Yan H; Pan XM; Feng XS
Transplant Proc; 2009 Jun; 41(5):1565-9. PubMed ID: 19545680
[TBL] [Abstract][Full Text] [Related]
2. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
[TBL] [Abstract][Full Text] [Related]
3. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Zhu X; Chen J; Han F; Cheng M; Xu L; Zhang L; Ding X; Le Y
Transplant Proc; 2009 Nov; 41(9):3736-42. PubMed ID: 19917377
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
[TBL] [Abstract][Full Text] [Related]
7. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
[TBL] [Abstract][Full Text] [Related]
8. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
[TBL] [Abstract][Full Text] [Related]
9. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation.
Min DI; Perry PJ; Chen HY; Hunsicker LG
Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147
[TBL] [Abstract][Full Text] [Related]
11. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
[TBL] [Abstract][Full Text] [Related]
12. Safety of low-dose cyclosporine therapy before transplantation in kidney allograft recipients.
Khosroshahi HT; Badrogli N; Jahannavard N; Oskuii R; Bahluli A; Azar SA; Ardalan M
Transplant Proc; 2009 Sep; 41(7):2757-60. PubMed ID: 19765427
[TBL] [Abstract][Full Text] [Related]
13. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
[TBL] [Abstract][Full Text] [Related]
14. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
15. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
[TBL] [Abstract][Full Text] [Related]
17. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
[TBL] [Abstract][Full Text] [Related]
18. [Completely reversed acute rejection episodes do not influence the long-term renal allograft survival].
Wu JY; Chen JH; Wang YM; Zhang JG; Zhu C; Wang SY; Zhang P; Huang HF; He Q
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(2):106-9. PubMed ID: 12812676
[TBL] [Abstract][Full Text] [Related]
19. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity.
Holzmacher R; Kendziorski C; Michael Hofman R; Jaffery J; Becker B; Djamali A
Nephrol Dial Transplant; 2005 Jul; 20(7):1456-62. PubMed ID: 15840674
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine challenge in the decision of combined kidney-pancreas versus solitary pancreas transplantation.
Brennan DC; Stratta RJ; Lowell JA; Miller SA; Taylor RJ
Transplantation; 1994 Jun; 57(11):1606-11. PubMed ID: 8009595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
